ANTIBACTERIAL BENZOTHIAZOLE DERIVATIVES

1 . A compound of formula I

wherein

R 1 is the group M, whereby M is one of the groups M A and M B represented below

wherein A represents a bond or C≡C;

R 1A is H or halogen;

R 2A is H or halogen; and

R 3A is H, (C 1 -C 3 )alkoxy, hydroxy(C 2 -C 4 )alkoxy, hydroxy(C 1 -C 4 )alkyl, dihydroxy(C 2 -C 4 )alkyl, 2-hydroxyacetamido, 1-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, 3-(hydroxy(C 1 -C 3 )alkyl)oxetan-3-yl, 3-aminooxetan-3-yl or 1-aminocycloprop-1-yl; and wherein

R 1B is hydroxy(C 1 -C 4 )alkyl, dihydroxy(C 2 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 3 )alkyl, 1-amino-cycloprop-1-yl, 1-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, trans-2-aminomethyl-cycloprop-1-yl, trans-2-hydroxymethyl-1-methyl-cycloprop-1-yl, trans-2-hydroxymethyl-2-methyl-cycloprop-1-yl, cis-1-fluoro-2-(hydroxymethyl)cycloprop-1yl, cis-2-fluoro-2-(hydroxymethyl)cycloprop-1-yl, 2-(1,2-dihydroxyethyl)-cycloprop-1yl, 1-(hydroxymethyl)-cyclobutan-1-yl, cis-3-(hydroxymethyl)-1-hydroxy-cyclobutan-1-yl, 3-hydroxyoxetan-3-yl, 3-hydroxyoxetan-3yl-(C 1 -C 3 )alkyl, 3-aminooxetan-3-yl, 3-hydroxymethyl-oxetan-3-yl, trans-(cis-3,4-dihydroxy)-cyclopent-1-yl, 3-hydroxymethylbicyclo[1,1,1]pentan-1yl, 4-hydroxytetrahydro-2H-pyran-4yl, or (3R,6S)-3-aminotetrahydro-2H-pyran-6-yl, piperidin-4-yl, 1-(2-hydroxyacetyl)piperidin-4-yl, 3-hydroxythietan-3yl, 1-(2-hydroxyacetyl)azetidin-3-yl or 1-glycylazetidin-3-yl;

or a salt thereof.

2 . The compound of formula I according to claim 1 , wherein R 1 is the group M A ;

or a salt thereof.

3 . The compound of formula I according to claim 2 , wherein

A represents a bond or C≡C;

R 1A is H or halogen;

R 2A is H; and

R 3A is (C 1 -C 3 )alkoxy, hydroxy(C 1 -C 4 )alkyl, 1-hydroxymethyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, or 3-aminooxetan-3-yl;

or a salt thereof.

4 . The compound of formula I according to claim 2 , wherein A represents a bond;

or a salt thereof.

5 . The compound of formula I according to claim 4 , wherein

R 1A is H or halogen;

R 2A is H; and

R 3A is (C 1 -C 3 )alkoxy;

or a salt thereof.

6 . The compound of formula I according to claim 2 , wherein A represents C≡C;

or a salt thereof.

7 . The compound of formula I according to claim 6 , wherein

R 1A and R 2A are both H; and

R 3A is hydroxy(C 1 -C 4 )alkyl, 1-hydroxymethyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, or 3-aminooxetan-3-yl;

or a salt thereof.

8 . The compound of formula I according to claim 1 , wherein

R 1 is the group M B ;

or a salt thereof.

9 . The compound of formula I according to claim 8 , wherein

R 1B is hydroxy(C 1 -C 4 )alkyl, dihydroxy(C 2 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 3 )alkyl, 1-amino-cycloprop-1-yl, 1-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-1-methyl-cycloprop-1-yl, cis-1-fluoro-2-(hydroxymethyl)cycloprop-1-yl, cis-2-fluoro-2-(hydroxymethyl)cycloprop-1-yl, 1-(hydroxymethyl)-cyclobutan-1-yl, cis-3-(hydroxymethyl)-1-hydroxy-cyclobutan-1-yl, 3-hydroxyoxetan-3-yl, 3-hydroxyoxetan-3-yl-(C 1 -C 3 )alkyl, 3-aminooxetan-3-yl, 3-hydroxymethyl-oxetan-3-yl, or trans-(cis-3,4-dihydroxy)-cyclopent-1-yl, 4-hydroxytetrahydro-2H-pyran-4-yl, (3R,6S)-3-aminotetrahydro-2H-pyran-6-yl, piperidin-4-yl, or 1-(2-hydroxyacetyl)piperidin-4-yl;

or a salt thereof.

10 . The compound of formula I according to claim 9 , wherein

R 1B is hydroxy(C 1 -C 4 )alkyl, dihydroxy(C 2 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, 1-amino-cycloprop-1-yl, 1-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-1-methyl-cycloprop-1-yl, cis-1-fluoro-2-(hydroxymethyl)cycloprop-1-yl, cis-2-fluoro-2-(hydroxymethyl)cycloprop-1-yl, 3-hydroxyoxetan-3-yl, 3-hydroxyoxetan-3-yl-(C 1 -C 3 )alkyl, 3-hydroxymethyl-oxetan-3-yl, or trans-(cis-3,4-dihydroxy)-cyclopent-1-yl;

or a salt thereof.

11 . The compound of formula I according to claim 1 , wherein

R 1 is the group M A , A represents a bond,

R 1A is halogen,

R 2A i s H, and

R 3A is (C 1 -C 3 )alkoxy; or

R 1 is the group M A , A represents C≡C,

R 1A and R 2A are both H, and

R 3A is 1-hydroxymethyl-cycloprop-1-yl;

or R 1 is the group M B and R 1B is di(C 1 -C 4 )alkylamino(C 1 -C 3 )alkyl, 1-(hydroxymethyl)-cyclobutan-1-yl, cis-3-(hydroxymethyl)-1-hydroxy-cyclobutan-1-yl, 3-aminooxetan-3-yl, 4-hydroxytetrahydro-2H-pyran-4-yl, (3R,6S)-3-aminotetrahydro-2H-pyran-6-yl, piperidin-4-yl, or 1-(2-hydroxyacetyl)piperidin-4-yl;

or a salt thereof.

12 . The compound of formula I according to claim 1 , wherein

A represents a bond or C≡C;

R 1A is H or halogen;

R 2A is H; and

R 3A is (C 1 -C 3 )alkoxy, hydroxy(C 1 -C 4 )alkyl, 1-hydroxymethyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, or 3-aminooxetan-3-yl;

and wherein R 1B is hydroxy(C 1 -C 4 )alkyl, dihydroxy(C 2 -C 4 )alkyl, amino(C 1 -C 4 )alkyl, di(C 1 -C 4 )alkylamino(C 1 -C 3 )alkyl, 1-amino-cycloprop-1-yl, 1-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-1-methyl-cycloprop-1-yl, cis-1-fluoro-2-(hydroxymethyl)cycloprop-1-yl, cis-2-fluoro-2-(hydroxymethyl)cycloprop-1-yl, 1-(hydroxymethyl)-cyclobutan-1-yl, cis-3-(hydroxymethyl)-1-hydroxy-cyclobutan-1-yl, 3-hydroxyoxetan-3-yl, 3-hydroxyoxetan-3-yl-(C 1 -C 3 )alkyl, 3-aminooxetan-3-yl, 3-hydroxymethyl-oxetan-3-yl, trans-(cis-3,4-dihydroxy)-cyclopent-1-yl, 4-hydroxytetrahydro-2H-pyran-4-yl, or (3R,6S)-3-aminotetrahydro-2H-pyran-6-yl, piperidin-4-yl, or 1-(2-hydroxyacetyl)piperidin-4-yl;

or a salt thereof.

13 . The compound of formula I according to claim 1 , wherein the compound is:

(R)-N-hydroxy-4-(6-((3-hydroxyoxetan-3-yl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-(2-fluoro-4-methoxyphenyl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((4-(3-hydroxyoxetan-3-yl)phenyl)ethynyl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-(5-hydroxy-5-methylhexa-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-((S)-5,6-dihydroxyhexa-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-(5-amino-5-methylhexa-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-(((1S,2S)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((1-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-((3-aminooxetan-3-yl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-((1-aminocyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((4-(1-(hydroxymethyl)cyclopropyl)phenyl)ethynyl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((1-(hydroxymethyl)cyclobutyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-(((1s,3R,4S)-3,4-dihydroxycyclopentyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-(5-(3-hydroxyoxetan-3-yl)penta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-(((1R,2R)-2-(hydroxymethyl)-1-methylcyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-(((2S,5R)-5-aminotetrahydro-2H-pyran-2-yl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-(5-(dimethylamino)penta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((4-hydroxytetrahydro-2H-pyran-4-yl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(6-(piperidin-4-ylbuta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)butanamide,

(R)-N-hydroxy-4-(6-((3-(hydroxymethyl)oxetan-3-yl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((cis-1-hydroxy-3-(hydroxymethyl)cyclobutyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((1-(2-hydroxyacetyl)piperidin-4-yl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-(((1R*,2R1-1-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, or

(R)-4-(6-(((1R*,2R*)-2-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

or a salt of such compound.

14 . The compound of formula I according to claim 1 , wherein the compound is:

(R)-N-hydroxy-4-(6-(4-methoxyphenyl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-((4-(hydroxymethyl)phenyl)ethynyl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(6-((4-(3-aminooxetan-3-yl)phenyl)ethynyl)-benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, or

(R)-N-hydroxy-4-(6-(5-hydroxypenta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

or a salt of such compound.

15 . The compound of formula I according to claim 1 , wherein the compound is:

(R)-N-hydroxy-4-(6-((1-(2-hydroxyacetyl)azetidin-3-yl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(6-(((1R,2S)-2-(hydroxymethyl)-2-methylcyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-2-methyl-2-(methylsulfonyl)butanamide, and or

(R)-4-(6-(((1R,2R)-2-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzo[d]thiazol-2-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

or a salt of such compound.

16 . The compound of formula I according to claim 1 , or a pharmaceutically acceptable salt thereof, formulated as a medicament.

17 . A pharmaceutical composition comprising, as active principle, the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

18 . A method of preventing or treating a bacterial infection comprising administering to a subject an amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

19 . The compound or pharmaceutically acceptable salt according to claim 18 , which is for the prevention or treatment of a Gram-negative bacterial infection.